Skip to main content
Clinical Trials/CTRI/2018/05/014237
CTRI/2018/05/014237
Completed
Phase 3

A randomized controlled single blind clinical trial to evaluate efficacy of empirical treatment with Albendazole in delaying disease progression amongst HIV positive ART naïve patients at an ART centre of a tertiary care hospital

AFMC0 sites160 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: null- HIV positive ART naive
Sponsor
AFMC
Enrollment
160
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 27, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
AFMC

Eligibility Criteria

Inclusion Criteria

  • HIV positive adults more than 18yrs of age
  • HIV positive patients not on ART
  • HIV positive patients not meeting WHO clinical criteria for initiation of ART
  • CD4 count \>500/mm3 at baseline

Exclusion Criteria

  • Patients who have opportunistic infection

Outcomes

Primary Outcomes

Not specified

Similar Trials